Navigation Links
HistoRx Names Bill Sullivan Senior Vice President, Diagnostic Operations
Date:7/17/2008

-Company ramps up clinical diagnostics product development-

NEW HAVEN, Conn., July 17 /PRNewswire/ -- HistoRx, Inc., announced today that William C. Sullivan has joined the company as Senior Vice President, Diagnostic Operations. In this newly created position, Mr. Sullivan will be responsible for expanding the role of the company's diagnostics development process, overseeing the manufacture of HistoRx diagnostic products, and growing revenues associated with the clinical diagnostics services provided by HistoRx.

"I am delighted to have this opportunity to join HistoRx at such a promising time for the company," said Mr. Sullivan. "HistoRx has made impressive progress over the past several years in building a company that is well-poised with its unique AQUA(R) technology platform to capitalize on the tremendous opportunity that personalized medicine represents, powered by an expanding revenue-generating services operation. I look forward to leading the commercial laboratory operations for HistoRx's growing number of pharmaceutical and biotechnology customers as we focus concurrently on developing and commercializing our own line of HistoRx high-value clinical diagnostic products."

"The HistoRx management team, operations workforce, and Board of Directors are very pleased to have Bill join the company," said Rana Gupta, CEO of HistoRx. "Over the past year, we have moved the company rapidly toward our ultimate goal of introducing HistoRx-branded, FDA-approved, quantitative diagnostic tests that run on the proprietary HistoRx AQUA(R) technology. We believe these assays will offer significant improvements over currently available immunohistochemistry-based tests and drive standards-based market adoption of our technology. With his impressive diagnostics industry expertise combined with operations management experience, Bill will be a tremendous asset to HistoRx in leading our commercial laboratory operations and diagnostic product development."

Mr. Sullivan brings to HistoRx an accomplished management record, with more than 25 years of experience leading operations of technology-driven businesses in the in vitro diagnostics and medical devices industries. He was previously Vice President, Corporate Operations of Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.); prior to that, he served as Vice President, Diagnostic Manufacturing at Visible Genetics and as Vice President, Operations at the Nichols Institute Diagnostics (a subsidiary of Quest Diagnostics), among positions with other diagnostics and medical device companies. Mr. Sullivan also served as a consultant to diagnostics and medical device companies, specializing in manufacturing operations for FDA-regulated facilities and products. He earned a B.A. from The College of the Holy Cross in Worcester, Massachusetts and pursued graduate studies in the Department of Pathology at the University of Pennsylvania.

About HistoRx ( http://www.historx.com )

HistoRx, Inc. is a leader in the emerging field of tissue-based diagnostic products for targeted patient treatment. HistoRx is developing and commercializing novel diagnostic products and services based on the company's pioneering AQUA(R) tissue biomarker analysis technology, which provides exceptional measurement and localization of protein biomarkers in their natural context within tissue. The proprietary AQUA(R) technology is the first platform capable of measuring biomarker concentration with subcellular resolution to generate more precise, efficient, and cost-effective answers about the safety and effectiveness of new therapeutics in development as well as enable the development of companion diagnostic tests for targeted therapies. HistoRx services are used by pharmaceutical and biotechnology companies throughout discovery research, preclinical studies, and clinical drug development. HistoRx also develops companion diagnostic products that are linked to partners' drug candidates in development to predict therapeutic outcome, which HistoRx will co-market with its partners' targeted therapeutics. These partnerships provide the basis for HistoRx to pursue internal programs to develop proprietary in vitro diagnostics that offer substantial improvements in treatment decision-making and patient outcomes compared with existing immunohistochemistry-based tests.

CONTACT:

Mary Moynihan

M2Friend Biocommunications

(802)951-9600

mary@m2friend.com


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
2. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
3. The TPAA Names Mark Oelschlager President
4. Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister
5. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
6. Metabolex Names Zhao, Martin to Executive Posts
7. IBT Laboratories Names Maureen Loftus President and Chief Operating Officer
8. J. Craig Venter Institute Names Robert Friedman, Ph.D., Deputy Director of West Coast Facility
9. FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008
10. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
11. Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017  Personal Genome Diagnostics Inc. ... testing contract with the U.S. Department of Veterans ... assay with the company,s new CancerSELECT ™ ... actionable pan-cancer profiling test that includes microsatellite instability ... patient response to checkpoint inhibitor immunotherapies. CancerSELECT 125 ...
(Date:3/22/2017)... FRANCISCO , March 22, 2017   ... fastest growing genetic information companies, today announced the ... diagnosis of Spinal Muscular Atrophy (SMA) , ... leading lethal genetic disorders among infants as well ... in childhood. The new test, announced during the ...
(Date:3/20/2017)... , ... March 20, 2017 ... ... that interfere with the ability of endogenous hormones to regulate homeostasis via ... binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological disorders. ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... (GI) disorders, today announced that it has entered into an exclusive global license ... inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
Breaking Biology News(10 mins):